Association of Therapeutic Mammoplasty and Radiotherapy Side-effects
Clinical Breast Cancer · 2026
DOI: 10.1016/j.clbc.2026.08.001 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Breast Cancer, 2026. Verfasst von Arjuna Brodie und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, University Hospitals of Leicester NHS Trust, Leicester, UK. Hauptthemen laut MEDLINE: Breast Neoplasms, Mammaplasty, Mastectomy, Segmental, Radiation Injuries. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
INTRODUCTION: Patients with larger breast size and volume are at increased risk of side-effects (toxicity) from radiotherapy. Therapeutic mammoplasty (TM) extends breast-conserving surgery by combining wide local excision of the cancer with breast reduction and mastopexy techniques. The aim of this study was to determine the effect of TM using level 2 oncoplastic techniques on the incidence of early and long-term radiotherapy side-effects. PATIENTS AND METHODS: Breast cancer patients recruited prospectively into the multicenter REQUITE cohort study (www.requite.eu) at a single institution (n = 346) were included. Radiotherapy side-effects (CTCAE v4.0) were scored at baseline, following radiotherapy, and at 2-year follow-up. The association of TM and specimen resection weight were investigated in multivariable regression models. RESULTS: At 2 years, 20.1 % of patients had grade ≥ 2 atrophy, 23.2% grade ≥ 1 tumor bed induration (fibrosis), 12.6% grade ≥ 1 breast induration, and 12.1% grade ≥ 1 telangiectasia. 22.5 % of patients (n = 78) underwent TM. TM patients had larger tumors (P = .006) and specimen resection weights (P < .001). TM but not specimen resection weight was associated with reduced tumor bed induration (Odds ratio = 0.12, 95% confidence interval [CI] 0.035-0.395, P = .001), breast induration (OR 0.19, CI 0.043-0.852, P = .03) and telangiectasia (OR 0.12, CI 0.020-0.736, P = .02). Neither TM nor specimen weight had any effect on atrophy or early radiotherapy side-effects. CONCLUSION: TM but not resected specimen weight was associated with fewer long-term radiotherapy side-effects. This implies that the incidence of side-effects is affected not by reducing the overall radiotherapy target volume but by re-shaping the breast, which is likely to reduce dose inhomogeneity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Breast Surgery, University Hospitals of Leicester NHS Trust, Leicester, UK.
- Department of Oncology, University Hospitals of Leicester NHS Trust, Leicester, UK.
- Division of Genetics and Genome Biology, University of Leicester, Leicester, UK.
- Department of Breast Surgery, University Hospitals of Leicester NHS Trust, Leicester, UK; Division of Cancer Sciences, University of Leicester, Leicester, UK. Electronic address: tr104@le.ac.uk.
Zitieren
APA
Brodie, A., Gaber, A., Kaushik, M., Krupa, J., Lambert, K. V., Pilgrim, S. M., Sasi, W., Valassiadou, K., Kancherla, K., Sampson, K., Talbot, C. J., & Rattay, T. (2026). Association of Therapeutic Mammoplasty and Radiotherapy Side-effects. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2026.08.001
Vancouver
Brodie A, Gaber A, Kaushik M, Krupa J, Lambert KV, Pilgrim SM, et al. Association of Therapeutic Mammoplasty and Radiotherapy Side-effects. Clinical Breast Cancer. 2026. doi:10.1016/j.clbc.2026.08.001
BibTeX
@article{Brodie2026,
author = {Brodie, Arjuna and Gaber, Ahmed and Kaushik, Monika and Krupa, Jaroslaw and Lambert, Kelly V and Pilgrim, Simon M and Sasi, Walid and Valassiadou, Kalliope and Kancherla, Kiran and Sampson, Kufre and Talbot, Christopher J and Rattay, Tim},
title = {Association of Therapeutic Mammoplasty and Radiotherapy Side-effects},
journal = {Clinical Breast Cancer},
year = {2026},
doi = {10.1016/j.clbc.2026.08.001}
}
EUVIMED